Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04587921
  4. Details
NCT04587921 Clinical Trial

Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19

Covid19 Clinical Trial

— MoxiCov  

Official title:
Feasibility and Impact of Remote Oximetry and Cardiac Frequency Monitoring in Patients Hospitalized and Isolated With Covid-19

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04587921
Other study ID # 5058/20/087
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 22, 2020
Est. completion date June 22, 2021

Study information
Verified date October 2020
Source University of Sao Paulo General Hospital
Contact Diego Prieto, Msc
Phone 55 11 994385300
Email diego.campos.prieto@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of MoxiCov is to monitor the oximetry of patients admitted to the Covid nursery to provide a more detailed assistance expecting to reduce the amount of hypoxia in these patients.

Recruitment information / eligibility
Status Recruiting
Enrollment 90
Est. completion date June 22, 2021
Est. primary completion date January 22, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Over 18 years old

- COVID 19 positive or suspected COVID19

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• Digital oximeter monitoring
Digital oximeter and cardiac frequency monitoring.

Locations
Country Name City State
Brazil Fundação Zerbini - Instituto do Coração (InCor) São Paulo SP

Sponsors (1)
Lead Sponsor Collaborator
University of Sao Paulo General Hospital

Country where clinical trial is conducted

Brazil, 

Outcome
Type Measure Description Time frame Safety issue
Primary Feasibility of the system: Determination of the number of valid versus not valid or missed measurements Determination of the number of valid versus not valid or missed measurements of each participant. 6 months
Primary Hypoxic burden Time spent with SpO2< 93%, 90% and 85% 6 months
Primary Hypoxic alarm Number of times the oximeter record 3 consecutive measurements of SpO2<90% 6 months
Primary Satisfaction of the nursing, medical team and patients with the implemented system Measurement of NET PROMOTING SCORE (NPS). This score will show the satisfaction of the healthcare team with the device. This score have a minimum of 0 points and maximum of 32 points. 6 months
Secondary Time of SpO2<90%, SpO2<85% and SpO2<80% 6 months
Secondary Number of false alarms caused by malfunctions or bad oximeter positioning 6 months
Secondary Total hospital stay 6 months
Secondary Time of supplementary oxygen use 6 months
Secondary Mortality of participants 6 months
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3